Navigation Links
Micromet Reports Fourth Quarter and Full Year 2009 Financial Results
Date:3/4/2010

omet-inc.com/">www.micromet-inc.com.

About Blinatumomab

Blinatumomab (MT103) is a novel, next-generation monoclonal antibody designed to direct the body's cell destroying T-cells against CD19, a protein expressed on the surface of most B-cell derived non Hodgkin's lymphomas. Blinatumomab has demonstrated potent activity against adult Acute Lymphocytic Leukemia, achieving an 80% molecular response rate in a Phase 2 study. Blinatumomab was generally well-tolerated by patients in the Phase 2 study.  The most frequently reported grade 3/4 adverse event was lymphopenia.  All other adverse events were infrequent and transient in nature.  Micromet received orphan drug designation from the EMEA for blinatumomab for the treatment of ALL in August 2009.

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® technology, as well as conventional mo
'/>"/>

SOURCE Micromet, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine news :

1. Data from Phase 1 Study Confirm High Response Rate of Micromets Blinatumomab in Patients with Non-Hodgkins Lymphoma
2. Micromet, Inc. Reports Second Quarter 2009 Financial Results
3. Phase 1 Study Initiated with Micromet Anti-GM-CS Human Antibody MT203
4. Micromet, Inc. Reports First Quarter 2009 Financial Results
5. Micromet To Present at the ROTH 21st Annual Orange County Growth Stock Conference
6. Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Presented at American Society of Hematology Annual Meeting
7. Micromet to Present at the Piper Jaffray 20th Annual Health Care Conference
8. Micromet, Inc. Reports Second Quarter 2008 Financial Results
9. Micromet, Inc. Reports First Quarter 2008 Financial Results
10. Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkins Lymphoma Patients
11. Micromets BiTE(R) Antibodies Reveal Unique Mode of Action
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... 24, 2014 (HealthDay News) -- Among early stage breast ... than half of one percent will eventually develop leukemia ... reveals. The finding comes from a review of ... and 2007, and it suggests that the risk for ... experts had previously thought. "The frequency of bone ...
(Date:12/25/2014)... New York (PRWEB) December 25, 2014 ... continue to move forward in a number of multidistrict ... of West Virginia, Bernstein Liebhard LLP reports. According to ... is scheduled to convene a Joint Status Conference in ... 10:00 a.m. Parties have been directed to submit a ...
(Date:12/25/2014)... North Carolina (PRWEB) December 25, 2014 ... North Carolina Retirement Community, recently showed their generous ... girls of the Catawba County Parenting Network- Grandparents ... the 10 children gathered around the largest Christmas ... to open presents purchased by residents of the ...
(Date:12/24/2014)... AlignLife of Wauwatosa loves helping those in the ... holiday season, AlignLife looks forward to their annual toy drive. ... Mahalko-Leonhardt, owner of AlignLife. "It brings our patients as well ... able to give kids toys for Christmas who would be ... of our patients." , The 70 toys were donated to ...
(Date:12/24/2014)... Connie Casad, MD, a well-known and respected ... 30 years of practice experience in Dallas, Texas, has ... of dietary detoxification. The second study is scheduled to ... from test patients who just completed a 21-day detoxification ... in conducting the study, Dr. Casad said, "About 10 ...
Breaking Medicine News(10 mins):Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4Health News:Retirement Community Residents Make Impact During Holiday Season 2Health News:AlignLife of Wauwatosa Brings Joy to Less Fortunate Families 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3
... 22, 2012) -- Up to half of all prostate cancer cells ... and formation of its unique protein -- but no one has ... College researchers have found that in these cancer cells, the 3-D ... a chromatin, is warped in such a way that a switch ...
... programs about teenage pregnancy -- "16 and Pregnant" and "Teen ... shows glamorized teenage pregnancy, while supporters said they discouraged it. ... they,re both right. The study, which will appear in ... students because of the high dropout rate associated with pregnancy ...
... for a female song sparrow to stray from her breeding ... new study shows that sleeping around can be costly. ... Naturalist, found that offspring conceived outside sparrows, social pairs ... The findings throw a monkey wrench into theories about why ...
... , TUESDAY, May 22 (HealthDay News) -- ... cancer in elderly people who had the screening for ... findings suggest that screenings should be made available to ... Dr. Therese Kerwel, research fellow at Grand Rapids Medical ...
... Environmental Health Sciences (NIEHS), part of the National Institutes ... Program (SRP) at the University of California, San Diego. ... will fund continued research on the molecular and genetic ... other hazardous waste sites. It is the third ...
... Law 42/2010, which extends the smoking ban to public places, ... (from 40.3% to 35.3%) and in consumption amongst the working ... ages and occupations. SINC , ... of Ibermutuamur (accidents and diseases mutual insurance for Social Security ...
Cached Medicine News:Health News:Scientists unravel role of fusion gene in prostate cancer 2Health News:Scientists unravel role of fusion gene in prostate cancer 3Health News:Scientists unravel role of fusion gene in prostate cancer 4Health News:Viewers' family background affects how they react to MTV shows 16 and Pregnant, Teen Mom 2Health News:Viewers' family background affects how they react to MTV shows 16 and Pregnant, Teen Mom 3Health News:For monogamous sparrows, it doesn't pay to stray (but they do it anyway) 2Health News:Colonoscopy May Detect Curable Cancer in Elderly: Study 2Health News:UC San Diego Superfund Research Program receives $15 million grant renewal 2Health News:5 percent of workers gave up smoking when the anti-tobacco law took effect 2
(Date:12/22/2014)... Dec. 22, 2014  CytoSorbents Corporation (OTCQB:CTSOD), a ... blood purification technology to help fight deadly inflammation ... countries worldwide, today announced the appointment of Dr. ... as its Senior Vice President of Clinical Development, ... Di Russo is an accomplished pediatric ...
(Date:12/22/2014)... , Dec. 22, 2014 Research and Markets ... of the "US Self-monitoring Blood Glucose Market" ... http://photos.prnewswire.com/prnh/20130307/600769 This market insight focuses on ... the United States . Reimbursement analysis ... Thorough product analyses for more than 73 SMBG meters ...
(Date:12/22/2014)...  ConvaTec, a privately-held medical products and technologies company, ... Chief Executive Officer of the company, effective December 22, ... .  "The Board of Directors of ConvaTec thanks Mr. ... past three years," said Magnus Lundberg , the ... that the company is well positioned for the future."  ...
Breaking Medicine Technology:CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5US Self-monitoring Blood Glucose Market 2ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2
... ADDISON, Texas, Oct. 13, 2011 ULURU Inc. (NYSE ... a binding letter of intent with Melmed Holdings AG, a company ... Under the terms of the agreement ULURU will license the ... formed to market Altrazeal® in the European Union. In exchange for ...
... Clean Holdings, Inc. (Nasdaq: UCTT ), a leading ... equipment, flat panel, medical, energy and research industries will release ... 24, 2011 after markets close. The Company will ... and management,s outlook at 1:45 pm PDT on Monday, October ...
Cached Medicine Technology:ULURU Inc. Announces Altrazeal® Agreement for the European Market 2ULURU Inc. Announces Altrazeal® Agreement for the European Market 3
Indications For Usage: , Thoracic surgery. , Broncho-spirometry. , Thoracoscopies. , Differential or selective lung ventilation. ...
... Double lumen ... one-lung ventilation., ... Tube is packaged ... tube-to-circuit adaptors, suction ...
The TCB Univent® allows easily collapsing one lung for thoracoscopic procedures....
... Used for endobronchial blockade ... right lung for procedures ... The set consists of ... and an Arndt Multiport ...
Medicine Products: